EVALUATION OF THE EFFICACY OF COMBINATION THERAPY OF VINPOCETINE AND WITHANIA SOMNIFERA METHANOLIC EXTRACT IN COGNITIVE IMPAIRMENT
Anwesha Mandal* and Kedar S. Prabhavalkar
ABSTRACT
Cognition dysfunction has been long associated as severe and neurological disorders and is a characteristic symptom associated with neurodegenerative disorders such as Alzheimer‘s disease. There are several approaches for the management of cognition. The cognition enhancers currently available in the market may be used to combat health conditions that interfere with the process of learning, motor control and the maintenance of a healthy emotional state. However these drugs only provide symptomatic relief and are associated with various side effects such as diarrhoea, nausea, insomnia etc. The current research study undertaken evaluated the effects of Vinpocetine and Withania somnifera methanolic extract in combination of half the
original doses reported in literature for attenuation of cognition. These drugs have been used individually but not in combination for the enhancement of cognition. In vitro models of Morris water maze, Novel object recognition tests showed favorable results for combination therapies. Similar results were observed on estimation of biochemical levels of acetylcholinesterase (AChE), malondialdehyde (MDA), catalase and superoxide dismutase (SOD). Overall, the combination therapies showed a better efficacy than their monotherapy treatment and also a similar efficacy to the standard marketed treatment, Mentat. These results can be considered given that the marketed preparation contains more than 20 active ingredients. The present study results suggest the augmentation of benefits of Vinpocetine and Withania somnifera methanolic extract combination in the treatment of cognitive impairments.
Keywords: Cognitive impairment, Vinpocetine, Withania somnifera, Acetylcholinesterase activity, Elevated maze test, SOD activity.
[Download Article]
[Download Certifiate]